Evidence map›Paper›PMID 35337289›Full record

Trial reportBMC infectious diseases2022

Malaria positivity following a single oral dose of azithromycin among children in Burkina Faso: a randomized controlled trial.

Jessica Brogdon, Clarisse Dah, Ali Sié, Mamadou Bountogo, Boubacar Coulibaly, Idrissa Kouanda, Mamadou Ouattara, Guillaume Compaoré, Eric Nebie, Mariam Seynou and 6 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04315272 (Gut and Azithromycin Mechanisms in Infants and Children II), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04315272 phase4completednot on this map

Gut and Azithromycin Mechanisms in Infants and Children II

TypeinterventionalSponsorUniversity of California, San FranciscoRan2020 to 2022Enrolled449ConditionsMalariaArmsAzithromycin, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Jessica BrogdonFrancis I Proctor Foundation, University of California, San Francisco, 490 Illinois Street, Floor 2, San Francisco, CA, 94158, USA.
Clarisse DahCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Ali SiéCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Mamadou BountogoCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Boubacar CoulibalyCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Idrissa KouandaCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Mamadou OuattaraCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Guillaume CompaoréCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Eric NebieCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Mariam SeynouCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Elodie LebasFrancis I Proctor Foundation, University of California, San Francisco, 490 Illinois Street, Floor 2, San Francisco, CA, 94158, USA.
Fanice NyatigoFrancis I Proctor Foundation, University of California, San Francisco, 490 Illinois Street, Floor 2, San Francisco, CA, 94158, USA.
Huiyu HuFrancis I Proctor Foundation, University of California, San Francisco, 490 Illinois Street, Floor 2, San Francisco, CA, 94158, USA.
Benjamin F ArnoldFrancis I Proctor Foundation, University of California, San Francisco, 490 Illinois Street, Floor 2, San Francisco, CA, 94158, USA.
Thomas M LietmanFrancis I Proctor Foundation, University of California, San Francisco, 490 Illinois Street, Floor 2, San Francisco, CA, 94158, USA.
Catherine E OldenburgFrancis I Proctor Foundation, University of California, San Francisco, 490 Illinois Street, Floor 2, San Francisco, CA, 94158, USA. catherine.oldenburg@ucsf.edu.
Centre de Recherche en Santé de Nouna · BFSan Francisco Foundation · US

Funding

Bill and Melinda Gates Foundation OPP1187628
6 · The paper itself

Abstract

backgroundAzithromycin is a broad-spectrum antibiotic that has moderate antimalarial activity and has been shown to reduce all-cause mortality when biannually administered to children under five in high mortality settings in sub-Saharan Africa. One potential mechanism for this observed reduction in mortality is via a reduction in malaria transmission.

methodsWe evaluated whether a single oral dose of azithromycin reduces malaria positivity by rapid diagnostic test (RDT). We conducted an individually randomized placebo-controlled trial in Burkina Faso during the high malaria transmission season in August 2020. Children aged 8 days to 59 months old were randomized to a single oral dose of azithromycin (20 mg/kg) or matching placebo. At baseline and 14 days following treatment, we administered a rapid diagnostic test (RDT) to detect Plasmodium falciparum and measured tympanic temperature for all children. Caregiver-reported adverse events and clinic visits were recorded at the day 14 visit.

resultsWe enrolled 449 children with 221 randomized to azithromycin and 228 to placebo. The median age was 32 months and 48% were female. A total of 8% of children had a positive RDT for malaria at baseline and 11% had a fever (tympanic temperature ≥ 37.5 °C). In the azithromycin arm, 8% of children had a positive RDT for malaria at 14 days compared to 7% in the placebo arm (P = 0.65). Fifteen percent of children in the azithromycin arm had a fever ≥ 37.5 °C compared to 21% in the placebo arm (P = 0.12). Caregivers of children in the azithromycin group had lower odds of reporting fever as an adverse event compared to children in the placebo group (OR 0.41, 95% CI 0.18-0.96, P = 0.04). Caregiver-reported clinic visits were uncommon, and there were no observed differences between arms (P = 0.32).

conclusionsWe did not find evidence that a single oral dose of azithromycin reduced malaria positivity during the high transmission season. Caregiver-reported fever occurred less often in children receiving azithromycin compared to placebo, indicating that azithromycin may have some effect on non-malarial infections. Trial registration Clinicaltrials.gov NCT04315272, registered 19/03/2020.

Indexed as

AntimalarialsMalariaAnti-Bacterial AgentsAzithromycinBurkina FasoChild, PreschoolFemaleHumansInfantInfant, NewbornMaleAnti-Bacterial AgentsAntimalarialsAzithromycinAzithromycinMalariaRandomized controlled trialSahel

Identifiers

PMID35337289
PMCPMC8957146
OpenAlexW4226296108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.